Paul B Manning's Net Worth
$337 Million
Who is Paul B Manning?
Paul B Manning has an estimated net worth of $337 Million. This is based on reported shares across multiple companies, which include Liquidia Corp, Verrica Pharmaceuticals Inc., Taysha Gene Therapies, Inc., Acumen Pharmaceuticals, Inc., AveXis, Inc., Candel Therapeutics, Inc., Dova Pharmaceuticals, Inc., Pasithea Therapeutics Corp., and PERRIGO CO.
SEC CIK
Paul B Manning's CIK is 0001494695
Past Insider Trading and Trends
2018 was Paul B Manning's most active year for acquiring shares with 20 total transactions. Paul B Manning's most active month to acquire stocks was the month of May. 2018 was Paul B Manning's most active year for disposing of shares, totalling 5 transactions. Paul B Manning's most active month to dispose stocks was the month of April. 2021 saw Paul B Manning paying a total of $14,410,287.67 for 1,822,087 shares, this is the most they've acquired in one year. In 2019 Paul B Manning cashed out on 12,979,016 shares for a total of $356,922,940.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Liquidia Corp (LQDA) Snapshot price: $9.2988
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +70.34% | 337.08K |
$8.90 | $2,999,994.20 | 816.31K |
Sep 12
| |||
Form 4
| +7.29% | 20.36K |
—
|
—
| 299.69K |
Jun 20
| |||
Form 4
|
∞
| 279.33K |
$7.16 | $2,000,002.80 | 279.33K |
Dec 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
∞
| 435.67K |
—
|
—
| 435.67K |
Mar 31
| |||
Form 4
|
∞
| 392.16K |
$5.10 | $1,999,995.60 | 392.16K |
Apr 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 20
| |||
Form 4
| +36.80% | 198.41K |
$2.52 | $500,000.76 | 737.65K |
Apr 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Verrica Pharmaceuticals Inc. (VRCA) Snapshot price: $1.9099
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +2.61% | 200K |
$5.02 | $1,004,000.00 | 7.85M |
Jul 24
| |||
Form 4
| +53.57% | 4.76M |
$2.10 | $9,999,998.40 | 13.65M |
Jul 5
| |||
Form 4
| +0.62% | 50K |
$9.36 | $467,905.29 | 8.15M |
Dec 2 - Dec 3
| |||
Form 4
|
∞
| 739.83K |
$14.75 | $10,912,492.50 | 739.83K |
Mar 25
| |||
Form 4
| +0.25% | 20K |
$9.09 | $181,800.00 | 8.1M |
Aug 20
| |||
Form 4
| +0.68% | 10K |
$8.55 | $85,500.00 | 1.48M |
Aug 18
| |||
Form 4
| +0.41% | 6K |
$6.92 | $41,520.00 | 1.47M |
Aug 17
| |||
Form 4
| +12.12% | 158.5K |
$6.44 | $1,020,985.00 | 1.47M |
Aug 13 - Aug 14
| |||
Form 4
| +0.26% | 20.89K |
$14.38 | $300,279.84 | 8.08M |
Oct 8 - Oct 10
| |||
Form 4
| +0.51% | 47.5K |
$11.17 | $530,811.18 | 9.37M |
Jan 7
| |||
Form 4
| +0.76% | 70.2K |
$14.15 | $993,021.16 | 9.32M |
Nov 12 - Nov 13
| |||
Form 4
| +3.35% | 300K |
$15.00 | $4,500,000.00 | 9.25M |
Jun 19
| |||
Form 4
| +0.43% | 33K |
$15.08 | $497,640.00 | 7.79M |
Aug 10
| |||
Form 4
| +33,441.77% | 9.14M |
—
|
—
| 9.17M |
Jun 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Taysha Gene Therapies, Inc. (TSHA) Snapshot price: $2.09
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.33M |
$2.25 | $2,999,999.25 | 1.33M |
Jun 27
| |||
Form 4
| +0.61% | 100K |
$1.63 | $163,000.00 | 16.57M |
Nov 17
| |||
Form 4
|
∞
| 16.47M |
$0.90 | $14,820,000.30 | 16.47M |
Aug 16
| |||
Form 4
| +1,054.84% | 1.5M |
$2.00 | $3,000,000.00 | 1.64M |
Oct 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
| +4.89% | 201.6K |
$7.80 | $1,571,809.68 | 4.32M |
Feb 2 - Feb 3
| |||
Form 4
| +6.88% | 2.2K |
$13.19 | $29,044.38 | 34.2K |
Nov 24
| |||
Form 4
| +166.67% | 20K |
$12.54 | $250,800.00 | 32K |
Nov 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
∞
| 12K |
$20.98 | $251,760.00 | 12K |
May 14
| |||
Form 4
|
∞
| 5.3M |
—
|
—
| 5.3M |
Sep 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Acumen Pharmaceuticals, Inc. (ABOS) Snapshot price: $2.18
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4,370.76% | 3.92M |
$16.00 |
—
| 4.01M |
Jul 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AveXis, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -1.46M |
—
|
—
|
0
|
May 15
| |||
Form 4
| +0.49% | 1.11K |
—
|
—
| 228.75K |
Mar 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 30
| |||
Form 4
| -19.44% | -289.86K |
$34.50 | -$9,999,997.50 | 1.2M |
Sep 13
| |||
Form 4
| +685.19% | 1.67M |
—
|
—
| 1.91M |
Feb 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||